Fig. 5: Validation of AKR1C1 as a prognostic marker of progestin resistance. | Laboratory Investigation

Fig. 5: Validation of AKR1C1 as a prognostic marker of progestin resistance.

From: Brusatol sensitizes endometrial hyperplasia and cancer to progestin by suppressing NRF2-TET1-AKR1C1-mediated progestin metabolism

Fig. 5

A Aberrant expression of AKR1C1 in endometrial hyperplasia tissues before and after progestin treatment. IHC assay was used to determine AKR1C1 expression in the patients with different responses to progestin as follows: CR complete response, PR partial response, NR no response. Original magnification in this panel is ×200. B Representative samples from a patient who underwent two progestin treatments cycles and the corresponding PR and CR results were observed. AKR1C1 expression was examined by IHC. Original magnification in the upper panel: ×100, lower panel: ×200. C Inverse expression patterns of AKR1C1 in stromal cells and glands. Red triangle, atrophic gland after progestin treatment with a good response; Blue triangle, hyperplasia gland after progestin treatment with poor response; Purple triangle, normal gland.

Back to article page